pillbase.ru

Arixtra

Active substance: fondaparinux

INJECTION, SOLUTION · FONDAPARINUX SODIUM 2.5 mg/.5mL

United StatesActive

Marketing holder: Mylan Institutional LLC

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 2
  • Arixtra
    fondaparinux sodium
    EMEA/H/C/000403
    Viatris Healthcare Limited
  • Quixidar
    fondaparinux sodium
    EMEA/H/C/000404
    Glaxo Group Ltd.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-4846-7b62-8e4b-494e89c8d4e3,01a1208c-75eb-79df-99a4-baa2c428a91f,01a1208e-76ed-7453-8489-69e2686eb20b,01a1208e-76f2-79f3-8b63-2950a868598c,01a1208e-e0d7-797a-b598-294900e039a4;count=28 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
67457-592
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 67457-592 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 67457-592 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 67457-592 · Verified 2026-10-09 · open in source